|Year : 2021 | Volume
| Issue : 1 | Page : 8
Traditional chinese medicine in ameliorating diabetic kidney disease via modulating gut microbiota
Yanan Yang, Chongming Wu
Pharmacology and Toxicology Research Center, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
|Date of Submission||17-May-2021|
|Date of Decision||26-Jun-2021|
|Date of Acceptance||05-Jul-2021|
|Date of Web Publication||09-Sep-2021|
Dr. Chongming Wu
Pharmacology and Toxicology Research Center, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, 9 Dongdan 3rd Alley, Dongcheng District, Beijing 100193
Source of Support: None, Conflict of Interest: None
Diabetic kidney disease (DKD), a major microvascular complication of diabetes mellitus, has become the second cause of end-stage renal disease enhancing the mortality rate of diabetes. However, there are still few treatment approaches to combat it. Traditional Chinese medicine (TCM) has been applied for a long time to treat DKD. However, there is a lack of research on how does TCM plays the role in treating DKD due to the complex of composition of TCM. In recent decade, gut microbiota is increasingly recognized for its contributions to host health, and the occurrence of gut–kidney axis also attracts many interests about microbiota in kidney injury. Some of the studies have already revealed that TCM can alleviate the symptoms of DKD through regulating gut microbiota and ameliorate a vicious circle caused by imbalance of gut–kidney axis. However, the problems of which specific species mediates the efficacy of TCM and how gut microbiota influences the process of DKD are urgent to solve. Therefore, this review systematically summarized the application of TCM and the importance of gut microbiota in DKD. More importantly, the review provided a new insight to find biomarkers for diagnosis and treatment of DKD. In future study, targeted manipulation of the gut microbiota will be progressively recognized as a way to enhance human health.
Keywords: Diabetic kidney disease, gut microbiota, gut-kidney axis, traditional Chinese medicine
|How to cite this article:|
Yang Y, Wu C. Traditional chinese medicine in ameliorating diabetic kidney disease via modulating gut microbiota. Integr Med Nephrol Androl 2021;8:8
|How to cite this URL:|
Yang Y, Wu C. Traditional chinese medicine in ameliorating diabetic kidney disease via modulating gut microbiota. Integr Med Nephrol Androl [serial online] 2021 [cited 2021 Oct 28];8:8. Available from: http://www.journal-imna.com/text.asp?2021/8/1/8/325833
| Introduction|| |
Diabetic kidney disease (DKD) is a typical microvascular complication of both two types of diabetes mellitus and has become the second cause of end-stage renal disease following glomerulonephritis. The clinical manifestations of DKD are proteinuria, edema, hypertension, and even along with renal failure, which will endanger the patient's life. In recent decades, mesenchymal stem or stromal cells, noncoding RNAs, exendin-4, and islet transplantation are regarded as novel therapeutic ways for fighting DKD. In addition, sirtuins, notch and thyroid hormone signal transduction, and renin-angiotensin system also play important roles in DKD therapy. Unfortunately, all these treatments have shortcomings, such as an antitransplant reaction. Hence, it is necessary to identify novel pharmacological targets and develop some safe and effective drugs to prevent or treat DKD.
Traditional Chinese medicine (TCM), which has been used to treat diabetes, atherosclerosis, and some difficult and complex diseases for thousands of years in China, also has been recognized as one of the effective approaches to combat DKD. It is characterized by high safety and less damage to the body compared with chemical or biological drugs due to its natural source. In addition, the therapeutic theory of TCM is regulating body function as a whole to relieve symptoms. DKD is caused by metabolic disease and diabetes, which accompanied with the disorder of overall metabolism, so the TCM has potential advantages for DKD treatment. Researches showed that Ophiopogon japonicus, Morus alba leaf, formononetin from Astragalus membranaceus, heteropolysaccharide from Moutan cortex, loganin from Cornus officinalis, astragaloside IV, and berberine are all good candidates for promoting the treatment of DKD.
However, the TCM is such a complex system that is difficult to explore the potential mechanism about how TCM could relieve DKD symptoms. Recently, a mounting number of studies focus on explaining the relationship between gut microbiota and human health. It is realized that gut microbiota not only plays a role in intestinal diseases and metabolic diseases, such as inflammatory bowel disease, diabetes, and hyperlipidemia, but also affects the development and treatment of some nervous system diseases and nephropathy, which is known as “gut–brain axis” and “gut–kidney axis.” Consequently, it is feasible to explore the therapeutic mechanism of TCM in ameliorating DKD based on gut microbiota.
Although some studies have been carried out to explore the role of gut microbiota in the diagnosis and treatment of DKD with TCM, these studies are relatively discrete, either focusing on the changes of microbiota or the effects of some intestinal metabolites. It did not connect the changes with the functions systematically, which will lead to a lack of profound understanding of the effect of gut microbiota on DKD development. Therefore, this review aimed to link the changes of gut microbiota with metabolic function and reveal the internal mechanism of TCM in treating DKD by regulating gut microbiota. Simultaneously, it provides a possible direction to explain the mechanism of TCM with modern pharmacology.
| Advances in the Treatment of Diabetic Kidney Disease with Traditional Chinese Medicine|| |
Traditional Chinese medicine or its active component alleviates diabetic kidney disease
One of the results of diabetic is leading to the occurrence of DKD, so the glycometabolism plays a crucial role in the development of DKD. The progressing researches have proved that some TCMs can alleviate the disorder of glycolipid metabolism, podocyte injury, basement membrane thickening, and glomerulosclerosis to alleviate the symptoms of DKD. For example, marein, the component of Coreopsis tinctoria Nutt, can protect renal injury by directly activating AMP-activated protein kinase/acetyl-CoA-carboxylase-2/peroxisome proliferator-activated receptor-gamma coactivator-1α signaling pathway and inhibiting sodium glucose transporter 2 expression. Mulberry leaf polysaccharide significantly reduces serum insulin, fasting blood glucose, 24-h urinary protein, and connective tissue growth factor (CTGF) in streptozotocin (STZ)-induced diabetic nephropathy rats.
Podocyte, attached to the outside of glomerular basement membrane, is an important barrier of glomerular hemofiltration. The occurrence of DKD always accompanied with the injury of podocyte. Research showed that the ATP-mediated intracellular calcium flux in the podocytes increased in DKD rat models. The podocyte-specific Dach1 transgenic overexpression can protect mice from DKD. Thus, targeting podocyte is an effective method for DKD therapy. Berberine, which is a quaternary ammonium alkaloid isolated from Coptis chinensis, can eliminate the activation of dynamin-related protein 1 induced by palmitic acid to stabilize the mitochondrial morphology of podocytes. Arctigenin is the main active component extracted from Fructus arctii, which increases the podocyte viability and function in DKD by improving podocyte adhesion, reducing motility, and regulating actin cytoskeleton, so it is a potential component that can be used to treat DKD. In addition, alleviating the symptom of DKD by astragaloside IV depends on transient receptor potential cation channel subfamily C member 6-mediated Ca2+ influx, which in turn reduces the podocyte apoptosis.
Inflammation is another typical symptom of DKD. A great deal of studies have revealed that the transforming growth factor (TGF)-β/mesenchymal transition or transdifferentiation (EMT), p38 mitogen-activated protein kinase (MAPK)/nuclear factor kappa B (NF-κB), Toll-like receptor 4 (TLR4)/NF-κB, and TGF-β1/small mothers against decapentaplegic (Smad) signaling pathways have a significant effect on diagnosis and treatment of DKD. Chrysophanol, also known as 1,8-dihydroxy-3-methyl-anthraquinone, a natural component from Rheum undulatum L., can downregulate the expression of p-smad2 and p-smad3 and deactivate the TGF-β/EMT signal in mice induced by high glucose so as to significantly alleviate the progression of DKD. Cordyceps cicadae polysaccharides and Bupleurum polysaccharide can relieve tubulointerstitial fibrosis in DKD rats through blocking the TLR4/NF-κB and TGF-β1/Smad signaling pathway and reducing inflammatory cytokine tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6 levels and TGF-β1-induced fibroblast activation. In addition to some phytomedicine, animal medicine, such as hirudin, can also reduce apoptosis of podocytes induced by high glucose and inhibit the expression of pro-inflammatory cytokines in the podocytes. These effects are achieved via inhibiting p38 MAPK/NF-κB activation in renal tissues and podocytes.
In a word, TCM or its active component alleviates the symptoms of DKD through protecting podocyte injury, improving metabolism, and reducing inflammation [Table 1].
|Table 1: The origin of active component in traditional Chinese medicine and its pathway or roles in diabetic kidney disease|
Click here to view
Traditional Chinese herbal formula alleviates the symptoms of diabetic kidney disease
The traditional Chinese herbal formula is formed based on the theory of “TCM formulation (Jun Chen Zuo Shi),” which can enhance curative effect and reduce toxicity. Some of the formulas used in the treatment of DKD are shown in [Table 2]. The Sang Tong Jian, from mulberry leaf, improves metabolic parameters related to blood glucose and blood lipids and then alleviates the damage of chronic diabetic nephropathy. However, QiDiTangShen granules obviously decrease urinary albumin excretion in db/db mice and reduces renal pathological damage without affecting body weight and blood glucose levels. It is speculated that different formulations have different effects on glucose in diabetic nephropathy mice, and further studies about whether the treatment of DKD is accompanied by the improvement of blood glucose level are needed. In addition, the serum metabolomics revealed that bekhogainsam decoction can change the pathway of metabolism, mainly including pathways of amino acid synthesis and metabolism, such as valine, leucine, isoleucine, tryptophans, and alanine.
|Table 2: The composition of Traditional Chinese Medicine formula and the pathway of its action|
Click here to view
Tangshen formula, which is the classical formulation used to treat diabetic nephropathy, can inhibit Jun N-terminal kinases and NF-κB signals so as to suppress the inflammation in the kidney. Meanwhile, Shenyan Kangfu tablet improving renal injury is also related to the inhibition of NF-κB in vivo and in vitro. Bu-Shen-Huo-Xue decoction improves renal function and podocyte epithelial–mesenchymal transition by inhibiting the Rac1/p21-activated kinase 1/p38 MAPK signaling pathway in high-fat diet/STZ-induced diabetic mice. In addition, jowiseungki decoction relieves the injury of diabetic nephropathy by improving renal interstitial fibrosis via NF-κB/α-smooth muscle actin pathway. Therefore, regulating inflammation can effectively ameliorate the symptoms of DKD.
| The Gut Microbiota is Involved in the Progress of Diabetic Kidney Disease|| |
Gut microbiota is a vital bridge that links the gut and kidney, which is known as “gut–kidney axis.” Specifically, the disorder of the normal gut microbiota can give rise to the injury of intestinal barrier. Then, the gut microbiota metabolites, such as trimethylamine N-oxide (TMAO), indoxyl sulfate (IS), and p-cresyl sulfate (PCS), will enter the body circulation and cause inflammation. In addition, the decrease of some probiotics and increase of some pathogenic bacteria also directly affect the normal renal function. Therefore, finding out whether gut microbiota mediates the treatment of DKD is the essential step to elaborate the mechanism of benefit effect of TCM. The changes of gut microbiota structure, usually assessed by its α-diversity and β-diversity, are the primary index to evaluate whether it is involved in the disease process. The DKD patients not only have decreased α-diversity of the gut microbiota but also have significantly changed β-diversity. There is a research showing that the combination of Scutellaria baicalensis Georgi. (SB) and Sophora japonica L. (SJ) can increase the α-diversity in hypertensive nephropathy rats. Simultaneously, Shenyan Kangfu tablet can change the structure of gut microbiota community assessed by β-diversity. Hence, it appears that gut microbiota indeed contributes to DKD therapeutic effect of TCM.
The study revealed that the species of Eggerthella lenta, Flavonifractor plautii, Alistipes finegoldii, and Alistipes shahii were enriched in patients with end-stage renal disease, while Prevotella copri and several butyrate producers, such as Roseburia spp., Faecalibacterium prausnitzii, and Eubacterium rectale, were depleted in patients. At the same time, the gut microbiota can interact with host genetics, which involved in the pathogenesis of immunoglobulin A nephropathy. Specifically, the risk genotype lysozyme-like 1, associated with higher serum levels of galactose-deficient-IgA1 and lower body mass index, was related to lower abundances of Dialister. The risk genotype signal-induced proliferation-associated 1-like protein 3, associated with a younger age, was related to lower abundances of Bacilli. However, the risk genotype phospholipid transfer protein, associated with worse kidney function and more severe microscopic hematuria, was relevant to higher abundances of Erysipelotrichaceae. The risk genotype AL365503.1, associated with a younger age and more severe hematuria, was relevant to higher abundances of Lachnobacterium. Therefore, the gut microbiota play an essential role in the renal disease. Similar to the end-stage renal disease and IgA nephropathy, a study showed that the genera of Megasphaera, Veillonella, Escherichia More Details-Shigella, Anaerostipes, and Haemophilus could be regarded as new potential biomarkers to provide a new strategy for DKD therapy.
Through digging deeper to elaborate the interaction between gut microbiota and renal function in nephropathy patients, we found that gut microbiota or its metabolites play an essential role in nephropathy. The recent studies demonstrated that two short-chain fatty acids (SCFAs)-producing bacteria, Succinivibrio and Anaerostipes, were dramatically reduced in death patients with chronic kidney disease, while the expansion of Bifidobacterium and Prevotella could enhance the concentration of SCFAs so as to prevent acute kidney injury. Further, the IgA nephropathy rat model possessed higher abundance of Lactobacillus reuteri, Rikenellaceae RC9, Ruminiclostridium 9, Actinobacteria, and Bifidobacterium, which is positively or negatively correlated with adipocytokine signaling pathway, caprolactam degradation, and so on. These results indicated that the gut microbiota could affect the progress of IgA nephropathy through altering metabolites.
The further exploration was performed to elaborate the molecular mechanism about how gut microbiota or its metabolites play a role in alleviating nephropathy. The study showed that lack of Myd88 in the intestinal epithelial cells could modulate inflammation in the kidney, which exhibiting the vital effect of gut–kidney axis in chronic kidney disease. The gut microbiota dysbiosis can also lead to immune activation and chronic inflammation, and this effect may be mediated by nuclear factor erythroid 2-related factor 2/NF-κB signaling pathway in M1 cells, the monocyte-derived macrophage. Furthermore, gut microbiota metabolizes tryptophan and produces a series of related metabolites, such as 5-hydroxytryptamine and kynurenine. Then, these tryptophan metabolites activate aryl hydrocarbon receptor signaling and lead to the occurrence of inflammation, oxidative stress injury, and chronic kidney diseases.
In summary, all these researches revealed that there is a potential connection between gut microbiota disorder and kidney dysfunction. Therefore, TCM may alleviate the symptoms of DKD via modulating gut microbiota dysbiosis and changing their metabolites.
| Traditional Chinese Medicine Alleviates the Progress of Diabetic Kidney Disease Via Regulating Gut Microbiota Composition|| |
The typical microbes in DKD mice are Escherichia-Shigella, Tyzzerella 3, Proteus, Marvinbryantia, and Ruminiclostridium 6. Magnesium lithospermate B, the water extracts from Salvia miltiorrhiza, can alter these compositions and form new structure of gut microbiota which consists of Odoribacter, Peptococcaceae, Bilophila, Enterorhabdus, Rhodococcus, and Candidatus saccharimonas. This implied that the causal relationship between DKD and this type of microbes should be further explored so as to understand the reason of occurrence of DKD.
Firmicutes, Bacteroidetes, Proteobacteria, and Actinobacteria are four dominant phyla in the human gut microbiota. One study uncovered that Bacteroidetes-to-Firmicutes ratio increased in DKD mice. Tangshen formula decreases Bacteroidetes-to-Actinobacteria ratio without influencing Bacteroidetes-to-Firmicutes ratio. Further, it enhances the relative abundance of Bifidobacteriaceae family but reduces Proteobacteria phylum, Enterobacteriaceae family, and Ruminococcus genus. It is known that Bacteroidetes is positively correlated with NF-κB, TNF-α and IL-1β protein expression. Shenyan Kangfu tablet increases the relative abundance of Firmicutes and decreased Bacteroidetes. These results suggest that Shenyan Kangfu tablet relieves inflammation by regulating gut microbiota. Resveratrol, a nature component, can reverse the disorder of gut microbiota characterized by lower abundance of Bacteroides, Alistipes, Rikenella, Odoribacter, Parabacteroides, and Alloprevotella genera in db/db mice, indicating the potential role of the microbiota in DKD treatment with resveratrol.
Moreover, 16S rRNA sequencing revealed that Cordyceps cicadae polysaccharides increased the relative abundance of probiotics, such as Desulfovibrionaceae, Oscillospira, Prevotellaceae, Paraprevotella, Ruminococcus, and Roseburia and decreased abundance of lipopolysaccharide-producing bacteria, thus recovered the disorder of gut microbiota in DKD mice. Jowiseungki decoction treatment can change the relative abundance of Alphaproteobacteria class, Atopobiaceae family, Acetatifactor, Butyricicoccus, Kerstersia, Peptococcus, and Coriobacteriaceae UCG-002 genus. Furthermore, Allobaculum and Anaerosporobacter can deteriorate renal function, but Blautia is the potential protective factor for DKD. In a word, gut microbiota is an effective mediator involved in alleviating symptoms of DKD by TCM [Table 3].
|Table 3: Traditional Chinese medicine and its active component modulate gut microbiota in diabetic kidney disease|
Click here to view
| Gut–Microbiota–Metabolite Axis is Closely Related to the Progress of Diabetic Kidney Disease|| |
The gut–microbiota–metabolite axis based on metabolomics is useful to find biomarker for diagnosis and treatment of disease. Many of the studies revealed that microbiota-derived metabolites mediate the occurrence and development of DKD mainly through two pathways.
SCFA, produced by gut microbiota, is an important source of nutrients for host intestinal cells and contributes to the regulation of the host immune system. On the one hand, Lactobacillaceae, Prevotellaceae, and Akkermansia can produce butyrate and lactic acid, regulate butyric acid and tryptophan metabolism, and lead to remission of renal metabolism., In DKD patients, some of these probiotics are decreased and their beneficial effects are weakened. On the other hand, excessive acetic acid due to the gut microbiota disorder may be involved in early DKD by activating the renin-angiotensin system. Specifically, the relative abundance of Blautia, Roseburia, and Paraprevotella increased, whereas Bacteroides decreased. These changes result in the increasing of plasma acetic acid and proteinuria, the thickening of glomerular basement membrane, and the disappearing of podocyte foot processes. In addition, acetic acid can activate G protein-coupled receptor 43 and increase the expression of TGF-β and CTGF proteins in HK-2 cells, which mediate fibrosis of renal tubulointerstitial in DKD.
Another aspect of effect of microbiota-derived metabolites on DKD is toxins such as IS, PCS, phenyl acetyl glutamine, indole-3 acetic acid, and TMAO. Destruction of the intestinal barrier in patients with DKD leads to the transfer of these toxins into the systemic circulation, causing inflammation and kidney injury. IS, PCS, and phenyl acetyl glutamine are negatively correlated with Ruminococcaceae, Lachnospiraceae, and Christensenellaceae, which can be regarded as early symbols of recession of kidney functions. The generation of phenyl sulfate relies on the gut microbiota-specific tyrosine phenol-lyase (TPL), which only expresses in Enterobacteriaceae. The TPL led dietary L-tyrosine synthesizes into phenol and further metabolizes into phenyl sulfate in the liver. Therefore, phenyl sulfate is a marker and a therapeutic target in DKD patients. Prebiotics or fiber-rich foods supplementation can decrease the serum PCS production. In addition, the level of TMAO has elevated in patients with chronic kidney disease, so the targeted inhibition of TMAO production will attenuate the development of chronic kidney disease.
| Conclusion and Prospect|| |
In summary, the composition and structure changes of gut microbiota obviously contribute to the process of DKD. The microbiota-derived metabolites including SCFAs, IS, PCS, and TMAO are involved in the diagnosis and treatment of DKD [Figure 1]. The increasing abundance of butyrate-produce bacteria, such as Lactobacillaceae, Prevotellaceae, and Akkermansia, may benefit the DKD patients, whereas the acetic acid-produce bacteria (Blautia, Roseburia, and Paraprevotella) and toxins-produce bacteria are harmful for DKD patients. Therefore, how to promote the colonization of butyrate-produce bacteria but inhibit acetic acid-produce bacteria is the effective approach to treat DKD.
There is no doubt that changes of gut microbiota and its metabolites may serve as clinical biomarkers for DKD diagnostics, prognostics, and monitoring. The study showed that the relative abundance of Escherichia-Shigella and Prevotella 9 was obviously different among diabetic patients and DKD patients and thus can be used to distinguish these two diseases in the process of diagnosis. Although such study already focused on finding differential microbiota to diagnose and treat diseases, most of the studies remain at the genus level. In the future, the specific species or strains should be further explored so as to find the more accurate biomarkers to promote the diagnosis and treatment of DKD.
|Figure 1: Traditional Chinese medicine in ameliorating diabetic nephropathy via modulating gut microbiota. Traditional Chinese medicine modulates the structure and composition of gut microbiota and then affects the production of microbiota-derived metabolites, such as short chain fatty acids, indoxyl-sulfate and so on. Some of these metabolites can improve renal function, while others can lead to renal injury. This regulation process is called “gut-kidney axis”. DKD is often accompanied by podocyte injury and inflammation. Some pathway such as TGF-β/ EMT, p38 MAPK/NF-κB, TLR4/NF-κB and TGF-β1/Smad often involved in the development of DKD. Traditional Chinese medicine can alleviate the symptoms of DKD by modulating gut microbiota and its metabolites. DKD: Diabetic kidney disease; EMT: Epithelial mesenchymal transition; MAPK: Mitogen-activated protein kinases; NF-κB: Nuclear transcription factor-κB; TCM: Traditional Chinese medicine; TGF-β: Transforming growth factor-β; TLR4: Toll-like receptor 4; Smad: Small mothers against decapentaplegic|
Click here to view
Moreover, the metabolites from gut microbiota also play a crucial role in the development of DKD. Current studies proved that uremic toxin, such as IS, PCS, and TMAO, were produced by proteolytic fermentation in nephropathy patients with typical gut microbiota disorders. These metabolites are regarded as markers and mediators of renal injury in DKD disease. In addition to paying attention to these harmful metabolites, it should also seek metabolites that can promote the amelioration of DKD. Next step is to associate the metabolites with specific species to increase the accuracy of DKD diagnosis and provide prospective approaches for targeted treatment of DKD.
The most difficult problem in clinical application of TCM is its multicomponent and complex mechanism. It may be the feasible direction to interpret the efficacy of TCM through associating gut microbiota or its metabolites with some disease-related factors. For instance, Kruppel-like factor-2 (KLF2) may play a role in glomerular endothelial cell injury in early DKD. Whether the expression of KLF2 is affected by the gut microbiota will be the promising direction in the future study.
Financial support and sponsorship
Conflicts of interest
Chongming Wu is an Editorial Board Member of the journal. The article was subject to the journal's standard procedures, with peer review handled independently of this editor and his research groups.
| References|| |
Wu Y, Zhang C, Guo R, et al
. Mesenchymal stem cells: An overview of their potential in cell-based therapy for diabetic nephropathy. Stem Cells Int 2021;2021:6620811.
Gu YY, Lu FH, Huang XR, et al
. Non-coding RNAs as biomarkers and therapeutic targets for diabetic kidney disease. Front Pharmacol 2020;11:583528.
Xie Z, Chen Z, Chen J. Combination therapy with exendin-4 and islet transplantation as a synergistic treatment for diabetic nephropathy in rats. Life Sci 2021;271:119207.
Zoja C, Xinaris C, Macconi D. Diabetic nephropathy: Novel molecular mechanisms and therapeutic targets. Front Pharmacol 2020;11:586892.
Zhu Y, Cong W, Shen L, et al
. Fecal metabonomic study of a polysaccharide, MDG-1 from Ophiopogon japonicus
on diabetic mice based on gas chromatography/time-of-flight mass spectrometry (GC TOF/MS). Mol Biosyst 2014;10:304-12.
Gurukar MS, Chilkunda ND. Morus alba
leaf bioactives modulate peroxisome proliferator activated receptor γ in the kidney of diabetic rat and impart beneficial Effect. J Agric Food Chem 2018;66:7923-34.
Zhuang K, Jiang X, Liu R, et al
. Formononetin activates the Nrf2/ARE signaling pathway via sirt1 to improve diabetic renal fibrosis. Front Pharmacol 2020;11:616378.
Lian Y, Zhu M, Chen J, et al
. Characterization of a novel polysaccharide from moutan cortex and its ameliorative effect on AGEs-induced diabetic nephropathy. Int J Biol Macromol 2021;176:589-600.
Du Q, Fu YX, Shu AM, et al
. Loganin alleviates macrophage infiltration and activation by inhibiting the MCP-1/CCR2 axis in diabetic nephropathy. Life Sci 2021;272:118808.
Xing L, Fang J, Zhu B, et al
. Astragaloside IV protects against podocyte apoptosis by inhibiting oxidative stress via activating PPARγ-Klotho-FoxO1 axis in diabetic nephropathy. Life Sci 2021;269:119068.
Wang YY, Tang LQ, Wei W. Berberine attenuates podocytes injury caused by exosomes derived from high glucose-induced mesangial cells through TGFβ1-PI3K/AKT pathway. Eur J Pharmacol 2018;824:185-92.
Ruigrok RA, Collij V, Sureda P, et al
. The composition and metabolic potential of the human small intestinal microbiota within the context of inflammatory bowel disease. J Crohns Colitis 2021;jjab020.
Ng SC, Xu Z, Mak JWY, Yang K, Liu Q, Zuo T, et al
. Microbiota engraftment after faecal microbiota transplantation in obese subjects with type 2 diabetes: A 24-week, double-blind, randomised controlled trial. Gut 2021;gutjnl-2020-323617.
Sun S, Araki Y, Hanzawa F, et al
. High sucrose diet-induced dysbiosis of gut microbiota promotes fatty liver and hyperlipidemia in rats. J Nutr Biochem 2021;93:108621.
Margolis KG, Cryan JF, Mayer EA. The microbiota-gut-brain axis: From motility to mood. Gastroenterology 2021;160:1486-501.
Ticinesi A, Milani C, Guerra A, et al
. Understanding the gut-kidney axis in nephrolithiasis: An analysis of the gut microbiota composition and functionality of stone formers. Gut 2018;67:2097-106.
Guo Y, Ran Z, Zhang Y, et al
. Marein ameliorates diabetic nephropathy by inhibiting renal sodium glucose transporter 2 and activating the AMPK signaling pathway in db/db mice and high glucose-treated HK-2 cells. Biomed Pharmacother 2020;131:110684.
Wu S. Mulberry leaf polysaccharides suppress renal fibrosis. Int J Biol Macromol 2019;124:1090-3.
Lin CL, Lee PH, Hsu YC, et al
. MicroRNA-29a promotion of nephrin acetylation ameliorates hyperglycemia-induced podocyte dysfunction. J Am Soc Nephrol 2014;25:1698-709.
Palygin O, Klemens CA, Isaeva E, et al
. Characterization of purinergic receptor 2 signaling in podocytes from diabetic kidneys. iScience 2021;24:102528.
Wang M. DACH1 protects podocytes and tubules from injury. Nat Rev Nephrol 2021;17:511.
Qin X, Zhao Y, Gong J, et al
. Berberine protects glomerular podocytes via inhibiting drp1-mediated mitochondrial fission and dysfunction. Theranostics 2019;9:1698-713.
Zhong Y, Lee K, Deng Y, et al
. Arctigenin attenuates diabetic kidney disease through the activation of PP2A in podocytes. Nat Commun 2019;10:4523.
Zang Y, Liu S, Cao A, et al
. Astragaloside IV inhibits palmitic acid-induced apoptosis through regulation of calcium homeostasis in mice podocytes. Mol Biol Rep 2021;48:1453-64.
Guo C, Wang Y, Piao Y, et al
. Chrysophanol inhibits the progression of diabetic nephropathy via inactivation of TGF-β pathway. Drug Des Devel Ther 2020;14:4951-62.
Han J, Pang X, Zhang Y, et al
. Hirudin protects against kidney damage in streptozotocin-induced diabetic nephropathy rats by inhibiting inflammation via P38 MAPK/NF-κB pathway. Drug Des Devel Ther 2020;14:3223-34.
Yang J, Dong H, Wang Y, et al
. Cordyceps cicadae polysaccharides ameliorated renal interstitial fibrosis in diabetic nephropathy rats by repressing inflammation and modulating gut microbiota dysbiosis. Int J Biol Macromol 2020;163:442-56.
Feng Y, Weng H, Ling L, et al
. Modulating the gut microbiota and inflammation is involved in the effect of Bupleurum polysaccharides against diabetic nephropathy in mice. Int J Biol Macromol 2019;132:1001-11.
Zhang Q, Lu Y, Ma Z, et al
. A novel formula from mulberry leaf ameliorates diabetic nephropathy in rats via inhibiting the TGF-β1 pathway. Food Funct 2015;6:3307-15.
Wei H, Wang L, An Z, et al
. QiDiTangShen granules modulated the gut microbiome composition and improved bile acid profiles in a mouse model of diabetic nephropathy. Biomed Pharmacother 2021;133:111061.
Meng X, Ma J, Kang AN, et al
. A Novel approach based on metabolomics coupled with intestinal flora analysis and network pharmacology to explain the mechanisms of action of bekhogainsam decoction in the improvement of symptoms of streptozotocin-induced diabetic nephropathy in mice. Front Pharmacol 2020;11:633.
Zhao T, Zhang H, Yin X, et al
. Tangshen formula modulates gut microbiota and reduces gut-derived toxins in diabetic nephropathy rats. Biomed Pharmacother 2020;129:110325.
Chen Q, Ren D, Wu J, et al
. Shenyan Kangfu tablet alleviates diabetic kidney disease through attenuating inflammation and modulating the gut microbiota. J Nat Med 2021;75:84-98.
Wang W, Long H, Huang W, et al
. Bu-Shen-Huo-Xue decoction ameliorates diabetic nephropathy by inhibiting Rac1/PAK1/p38MAPK Signaling Pathway in high-fat diet/streptozotocin-induced diabetic mice. Front Pharmacol 2020;11:587663.
Meng X, Ma J, Kang SY, et al
. Jowiseungki decoction affects diabetic nephropathy in mice through renal injury inhibition as evidenced by network pharmacology and gut microbiota analyses. Chin Med 2020;15:24.
Tang WH, Wang Z, Kennedy DJ, et al
. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res 2015;116:448-55.
Di Iorio BR, Rocchetti MT, De Angelis M, et al
. Nutritional therapy modulates intestinal microbiota and reduces serum levels of total and free indoxyl sulfate and P-cresyl sulfate in chronic kidney disease (Medika Study). J Clin Med 2019;8:1424.
Du X, Liu J, Xue Y, et al
. Alteration of gut microbial profile in patients with diabetic nephropathy. Endocrine 2021;73:71-84.
Guan Y, Chen K, Quan D, et al
. The combination of Scutellaria baicalensis
Georgi and Sophora japonica
L. ameliorate renal function by regulating gut microbiota in spontaneously hypertensive rats. Front Pharmacol 2020;11:575294.
Wang X, Yang S, Li S, et al
. Aberrant gut microbiota alters host metabolome and impacts renal failure in humans and rodents. Gut 2020;69:2131-42.
He JW, Zhou XJ, Li YF, et al
. Associations of genetic variants contributing to gut microbiota composition in immunoglobin A nephropathy. mSystems 12;6:e00819-20.
Lin TY, Wu PH, Lin YT, et al
. Gut dysbiosis and mortality in hemodialysis patients. NPJ Biofilms Microbiomes 2021;7:20.
Liu Y, Li YJ, Loh YW, et al
. Fiber derived microbial metabolites prevent acute kidney injury through g-protein coupled receptors and HDAC inhibition. Front Cell Dev Biol 2021;9:648639.
Li J, Cao Y, Lu R, et al
. Integrated fecal microbiome and serum metabolomics analysis reveals abnormal changes in rats with immunoglobulin A nephropathy and the intervention effect of Zhen Wu Tang. Front Pharmacol 2020;11:606689.
Watanabe IK, Andrade-Silva M, Foresto-Neto O, et al
. Gut microbiota and intestinal epithelial Myd88 signaling are crucial for renal injury in UUO mice. Front Immunol 2020;11:578623.
Lai L, Li Y, Liu J, et al
. Bovine serum albumin aggravates macrophage M1 activation and kidney injury in heterozygous Klotho-deficient mice via the gut microbiota-immune axis. Int J Biol Sci 2021;17:742-55.
Liu JR, Miao H, Deng DQ, et al
. Gut microbiota-derived tryptophan metabolism mediates renal fibrosis by aryl hydrocarbon receptor signaling activation. Cell Mol Life Sci 2021;78:909-22.
Zhao J, Zhang QL, Shen JH, et al
. Magnesium lithospermate B improves the gut microbiome and bile acid metabolic profiles in a mouse model of diabetic nephropathy. Acta Pharmacol Sin 2019;40:507-13.
Cai TT, Ye XL, Li RR, et al
. Resveratrol modulates the gut microbiota and inflammation to protect against diabetic nephropathy in mice. Front Pharmacol 2020;11:1249.
Li Y, Su X, Gao Y, et al
. The potential role of the gut microbiota in modulating renal function in experimental diabetic nephropathy murine models established in same environment. Biochim Biophys Acta Mol Basis Dis 2020;1866:165764.
Lau WL, Chang Y, Vaziri ND. The consequences of altered microbiota in immune-related chronic kidney disease. Nephrol Dial Transplant 2020;gfaa087.
Lu CC, Hu ZB, Wang R, et al
. Gut microbiota dysbiosis-induced activation of the intrarenal renin-angiotensin system is involved in kidney injuries in rat diabetic nephropathy. Acta Pharmacol Sin 2020;41:1111-8.
Hu ZB, Lu J, Chen PP, et al
. Dysbiosis of intestinal microbiota mediates tubulointerstitial injury in diabetic nephropathy via the disruption of cholesterol homeostasis. Theranostics 2020;10:2803-16.
Chen YY, Chen DQ, Chen L, et al
. Microbiome-metabolome reveals the contribution of gut-kidney axis on kidney disease. J Transl Med 2019;17:5.
Barrios C, Beaumont M, Pallister T, et al
. Gut-microbiota-metabolite axis in early renal function decline. PLoS One 2015;10:e0134311.
Kikuchi K, Saigusa D, Kanemitsu Y, et al
. Gut microbiome-derived phenyl sulfate contributes to albuminuria in diabetic kidney disease. Nat Commun 2019;10:1835.
Li YJ, Chen X, Kwan TK, et al
. Dietary fiber protects against diabetic nephropathy through short-chain fatty acid-mediated activation of G protein-coupled receptors GPR43 and GPR109A. J Am Soc Nephrol 2020;31:1267-81.
Zhong F, Chen H, Wei C, et al
. Reduced Krüppel-like factor 2 expression may aggravate the endothelial injury of diabetic nephropathy. Kidney Int 2015;87:382-95.
[Table 1], [Table 2], [Table 3]